P3T for Roche’s Giredestrant was approved in Korea
By Lee, Hye-Kyung | translator Alice Kang
22.04.12 06:00:32
가나다라
0
To be conducted in 7 hospitals including Seoul St.Mary’s Hospital… will evaluate the safety and efficacy of the drug as a combination therapy
The Ministry of Food and Drug Safety approved the company’s application to conduct a randomized, open-label Phase III trial to evaluate the efficacy and safety of ‘giredestrant+ Phesgo’ in comparison to Phesgo in treatment-naïve HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer patients after ‘Phesgo+taxane’ induction therapy.
The domestic Phase III trial will be conducted in Seoul St.Mary’s Hospital, Kyungpook National University Chilgok Hospital, the National Cancer Center, Seoul Asan Medical Center, Severance Hospital, an
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)